These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28251952)

  • 1. [Influence of doxorubicin inclusion into phospholipid nanoparticles on tumor accumulation and specific activity].
    Medvedeva NV; Torkhovskaya TI; Kostryukova LV; Zakharova TS; Kudinov VA; Kasatkina EO; Prozorovskiy VN; Ipatova OM
    Biomed Khim; 2017 Jan; 63(1):56-61. PubMed ID: 28251952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model.
    Zykova MG; Medvedeva NV; Torkhovskaya TI; Tikhonova EG; Prozorovskii VN; Zakharova TS; Ipatova OM
    Exp Oncol; 2012 Dec; 34(4):323-6. PubMed ID: 23302989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The influence of doxorubicin incorporated in phospholipid drug delivery nanosystem on HEPG2 cells proteome].
    Kuznetzova KG; Kazlas EV; Torkhovskaya TI; Karalkin PA; Vachrushev IV; Zakharova TS; Sanzhakov MA; Moshkovskiy SA; Ipatova OM
    Biomed Khim; 2015; 61(3):343-9. PubMed ID: 26215411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
    Harasym TO; Cullis PR; Bally MB
    Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Study of Pharmacological Properties of Doxorubicin-NPh.
    Nemtsova ER; Tikhonova EG; Bezborodova OA; Pankratov AA; Venediktova JB; Korotkevich EI; Kostryukova LV; Tereshkina JA
    Bull Exp Biol Med; 2020 Oct; 169(6):778-782. PubMed ID: 33123920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The in vivo study of the medicinal composition property of doxorubicin as a part of colloidal nanoparticles with the address fragment].
    Sanzhakov MA; Ignatov DV; Kostryukova LV; Druzhilovskaya OS; Medvedeva NV; Prozorovskyi VN; Ipatova OM
    Biomed Khim; 2016; 62(2):150-3. PubMed ID: 27143371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin.
    Tang N; Du G; Wang N; Liu C; Hang H; Liang W
    J Natl Cancer Inst; 2007 Jul; 99(13):1004-15. PubMed ID: 17596572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of drug loaded glycyrrhetinic acid modified alginate nanoparticles on mice bearing orthotopic liver tumor.
    Zhang C; Wu Y; Liu T; Zhao Y; Wang X; Wang W; Yuan Z
    J Control Release; 2011 Nov; 152 Suppl 1():e111-3. PubMed ID: 22195787
    [No Abstract]   [Full Text] [Related]  

  • 10. Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma.
    Mastria EM; Chen M; McDaniel JR; Li X; Hyun J; Dewhirst MW; Chilkoti A
    J Control Release; 2015 Jun; 208():52-8. PubMed ID: 25637704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice.
    Harivardhan Reddy L; Sharma RK; Chuttani K; Mishra AK; Murthy RS
    J Control Release; 2005 Jul; 105(3):185-98. PubMed ID: 15921775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possibilities for use of phospholipid nanosystem with glycyrrhizic acid ("phosphogliv") for optimization of drugs: doxorubicin and budesonide as examples].
    Ipatova OM; Zykova MG; Prozorovskiĭ VN; Torkhovskaia TI; Zakharova TS
    Biomed Khim; 2009; 55(2):185-94. PubMed ID: 19507342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 2-Isobutyl-4,6-dimethyl-5-hydroxypyrimidine on the Growth of Lewis Lung Carcinoma and Survival of Mice.
    Kovakenko LP; Kuznetsova OS; Tallerova AV; Nikitin SV; Durnev AD
    Bull Exp Biol Med; 2016 May; 161(1):99-103. PubMed ID: 27265128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.
    Tinkov S; Winter G; Coester C; Bekeredjian R
    J Control Release; 2010 Apr; 143(1):143-50. PubMed ID: 20060861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipd formulation].
    Zyova MA; Ipatova OM; Prozorovskiĭ VN; Medvedeva NV; Voskresenskaia AA; Zakharova TS; Torkhovskaia TI
    Biomed Khim; 2011; 57(2):174-9. PubMed ID: 21870602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II-induced hypertension enhanced therapeutic efficacy of liposomal doxorubicin in tumor-bearing mice.
    Hattori Y; Ubukata H; Kawano K; Maitani Y
    Int J Pharm; 2011 Jan; 403(1-2):178-84. PubMed ID: 20934498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
    Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
    Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.